Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, Bernard, Wanner, Christoph, Lachin, John M., Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa +4 more·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1504720

Cited by (12,156)

Items 801–900 of 12,156

  1. Mitochondrial Mechanisms in Diabetic Cardiomyopathy
    Johannes Gollmer, Andreas Zirlik, Heiko Bugger · 2020 · Diabetes & Metabolism Journal
  2. SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
    Yoshifumi Saisho · 2020 · Diseases
  3. Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial
    Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Muhammad Shahzeb Khan, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra et al. · 2020 · European Journal of Heart Failure
  4. Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association
    Tak Kwan, Sally Sukman Wong, Yuling Hong, Alka M. Kanaya, Sadiya S. Khan, Laura Lucia Hayman, Svati Hasmukh Shah, Francine K. Welty, PRAKASH C. DEEDWANIA, Asma Khaliq et al. · 2023 · Circulation
  5. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
    Lam, Carolyn S.P., Ramasundarahettige, Chinthanie, Branch, Kelley R.H., Sattar, Naveed, Rosenstock, Julio, Pratley, Richard, Del Prato, Stefano, Lopes, Renato D., Niemoeller, Elisabeth, Khurmi, Nardev S. et al. · 2022 · Circulation
  6. Empagliflozin’s Fuel Hypothesis: Not so Soon
    Gary D. Lopaschuk, Subodh Verma · 2016 · Cell Metabolism
  7. Acute kidney injury from SGLT2 inhibitors: potential mechanisms
    Kai M. Hahn, Ahsan A. Ejaz, Mehmet Kanbay, Miguel Angel Lanaspa, Richard J. Johnson · 2016 · Nature Reviews Nephrology
  8. Dapagliflozin in patients with heart failure and reduced ejection fraction
    Gruppo di Autoformazione Metodologica (GrAM), Giorgio Colombo, Rosa Casella, Alessia Cazzaniga, Chiara Casiraghi · 2020 · Internal and Emergency Medicine
  9. Endothelial Glycocalyx
    Christopher A Foote, Rogério N. Soares, Francisco I. Ramirez‐Perez, Thaysa Ghiarone, Annayya Rao Aroor, Camila Manrique‐Acevedo, Jaume Padilla, Luis Arturo Martinez‐Lemus · 2022 · Comprehensive physiology
  10. Epigenetic programming, early life nutrition and the risk of metabolic disease
    Block, Tomasz, El-Osta, Assam · 2017 · Atherosclerosis
  11. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
    Michael A. Pfeifer, Raymond R. Townsend, Michael J. Davies, Ujjwala Vijapurkar, Jimmy Ren · 2017 · Cardiovascular Diabetology
  12. Heart Failure With Preserved Ejection Fraction Expert Panel Report
    Kishan S. Parikh, Kavita Sharma, Mona Fiuzat, Howard K. Surks, Jyothis Thomas George, Narimon Honarpour, Christophe Depré, Patrice M. Desvigne-Nickens, Richard Nkulikiyinka, Gregory D. Lewis et al. · 2018 · JACC Heart Failure
  13. Angiotensin II‐induced redox‐sensitive SGLT1 and 2 expression promotes high glucose‐induced endothelial cell senescence
    Sonia Khemais‐Benkhiat, Eugenia Belcastro, Noureddine Idris-Khodja, Sin‐Hee Park, Lamia Amoura, Malak Abbas, Cyril Auger, Laurence Kessler, Eric Mayoux, Florence Toti et al. · 2019 · Journal of Cellular and Molecular Medicine
  14. Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
    Brendon Lange Neuen, Toshiaki Ohkuma, Bruce Charles Neal, David Richard Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh et al. · 2019 · Journal of the American Society of Nephrology
  15. Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure: Beyond Glycaemic Control. A Position Paper of the Heart Failure Association of the European Society of Cardiology
    Petar M Seferovic, Gabriele Fragasso, Mark Colquhoun Petrie, Wilfried Müllens, Roberto Ferrari, Thomas Thum, Johann K Bauersachs, Stefan D. Anker, Robin Ray, Yüksel Çavuşoğlu et al. · 2020 · European Journal of Heart Failure
  16. SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
    Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, Wojciech Garczorz, Karolina Zimmer, Tomasz Piotr Ilczak, Michał Ćwiertnia, Maciej Błażej Hajduga · 2022 · Cancers
  17. Sex and gender differences in myocarditis and dilated cardiomyopathy: An update
    Fairweather, DeLisa, Beetler, Danielle J., Musigk, Nicolas, Heidecker, Bettina, Lyle, Melissa A., Cooper, Leslie T., Bruno, Katelyn A. · 2023 · Frontiers in Cardiovascular Medicine
  18. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide
    Georgianos, Panagiotis I., Agarwal, Rajiv · 2019 · Diabetes Care
  19. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
    Katherine J. Kearney, Darren Charles Tomlinson, Kerrie A. Smith, Ramzi Ajjan · 2017 · Cardiovascular Diabetology
  20. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials
    Adriana Sánchez‐García, Mario Alberto Simental-Mendía, Juan Manuel Millán-Alanís, Luis E. Simental‐Mendía · 2020 · Pharmacological Research
  21. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
    Adriana Marton, Tatsuroh Kaneko, Jean‐Paul Kovalik, Atsutaka Yasui, Akira Nishiyama, Kento Kitada, Jens Marc Titze · 2020 · Nature Reviews Nephrology
  22. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation
    Sergio Raposeiras‐Roubín, Ignacio Jesus Amat-Santos, Xavier Rosselló, Rocío González-Ferreiro, Inmaculada González Bermúdez, Diego López‐Otero, Luis Nombela-Franco y, Livia Luciana Gheorghe, Jose L. Diez, Carlos Baladrón et al. · 2025 · New England Journal of Medicine
  23. Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88
    Lind, Marcus, Imberg, Henrik, Coleman, Ruth L., Nerman, Olle, Holman, Rury R. · 2021 · Diabetes Care
  24. Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis
    Harindra Rajasekeran, Yuliya Lytvyn, David Z.I. Cherney · 2016 · Kidney International
  25. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
    Samy Suissa · 2017 · Diabetes Care
  26. Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
    Ting-I Lee, Yao‐Chang Chen, Yung‐Kuo Lin, Cheng‐Chih Chung, Yen‐Yu Lu, Yu‐Hsun Kao, Yi‐Jen Chen · 2019 · International Journal of Molecular Sciences
  27. Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity
    Uwe Querfeld, ROBERT H. K. MAK, Axel Radlach Pries · 2020 · Clinical Science
  28. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
    Katherine R. Tuttle, Frank Chip Brosius, Matthew Aaron Cavender, Paola Fioretto, Kevin John Fowler, Hiddo J.L. Heerspink, Tom Manley, Darren K. McGuire, Mark E. Molitch, Amy K. Mottl et al. · 2020 · American Journal of Kidney Diseases
  29. Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
    Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting‐Yu Chiou, Tian‐Huei Chu, Lung‐Chih Li, Hwee‐Yeong Ng, Wen‐Chin Lee, Chien‐Te Lee · 2021 · Antioxidants
  30. Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
    William Durante, Ghazaleh Behnammanesh, Kelly J. Peyton · 2021 · International Journal of Molecular Sciences
  31. The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases
    Aikaterini Andreadi, Alfonso Bellia, Nicola Di Daniele, Marco Meloni, Renato Lauro, David Della‐Morte, Davide Lauro · 2021 · Current Opinion in Pharmacology
  32. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes
    Raffaele Marfella, Lucia Scisciola, Nunzia D’Onofrio, Ciro Maiello, Maria Consiglia Trotta, Celestino Sardu, Iacopo Panarese, Franca Ferraraccio, Annalisa Capuano, Michelangela Barbieri et al. · 2022 · Pharmacological Research
  33. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication
    Mancia, Giuseppe, Cannon, Christopher P., Tikkanen, Ilkka, Zeller, Cordula, Ley, Ludwin, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik · 2016 · Hypertension
  34. Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review
    Williams, Scott M., Eleftheriadou, Aikaterini, Alam, Uazman, Cuthbertson, Daniel J., Wilding, John P. H. · 2019 · Diabetes Therapy
  35. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
    Eirik Wigtil Søfteland, Juris Jendrik Meier, Bente Vangen, Robert Toorawa, Mario Maldonado‐Lutomirsky, Uli C. Broedl · 2016 · Diabetes Care
  36. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease ― Results From EMPA-REG OUTCOME® ―
    Kohei Kaku, Jisoo Lee, Michaela Mattheus, Stefan Kaspers, Jyothis Thomas George, Hans‐Juergen Woerle, on behalf of the EMPA-REG OUTCOME® Investigators · 2016 · Circulation Journal
  37. Co‐morbidities and co‐medications as confounders of cardioprotection—Does it matter in the clinical setting?
    Petra Kleinbongard, Hans Erik Bøtker, Michel Ovize, Derek John Hausenloy, Gerd Heusch · 2019 · British Journal of Pharmacology
  38. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
    Donato Cappetta, Antonella De Angelis, Loreta Pia Ciuffreda, Raffaele Coppini, Anna Cozzolino, Agostino Miccichè, Carmela Dell’Aversana, Domenico D’Amario, Eleonora Cianflone, Cristina Scavone et al. · 2020 · Pharmacological Research
  39. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
    Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo, Stefan D. Anker, Javed Butler, Andrew J.S. Coats, Gerasimos S Filippatos, Stephen John Greene, Theresa A. McDonagh, Piotr P. Ponikowski et al. · 2021 · European Journal of Heart Failure
  40. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis
    Rongjun Zou, Wanting Shi, Junxiong Qiu, Na Zhou, Na Du, Hao Zhou, Xinxin Chen, Li Ma · 2022 · Cardiovascular Diabetology
  41. SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
    Ashish Upadhyay · 2024 · Kidney360
  42. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
    On behalf of the EMPA-REG EXTEND™ MONO investigators, Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Péter Stella, Hans Juergen Woerle, Uli C. Broedl · 2015 · Cardiovascular Diabetology
  43. Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes
    James J. Chamberlain, William H. Herman, Sandra Leal, Andrew S. Rhinehart, Jay H. Shubrook, NEIL SKOLNIK, Rita Rastogi Kalyani · 2017 · Annals of Internal Medicine
  44. Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis
    Xinlin Zhang, Qingqing Zhu, Yuhan Chen, Xueling Li, Fu Chen, Jianan Huang, Biao Xu · 2018 · Journal of the American Heart Association
  45. Composite End Points in Clinical Research
    Paul W. Armstrong, Cynthia M. Westerhout · 2017 · Circulation
  46. Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
    Theresa A. McDonagh, Marco Metra, Marianna Adamo, Roy S. Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Dragomir Chioncel et al. · 2022 · Revista Española de Cardiología
  47. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
    Lucia Scisciola, Vittoria Cataldo, Fatemeh Taktaz, Rosaria Anna Fontanella, Ada Pesapane, Puja Ghosh, Martina Franzese, Armando Puocci, Antonella De Angelis, Liberata Sportiello et al. · 2022 · Frontiers in Cardiovascular Medicine
  48. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis
    Muhammad Usman, Deepak L. Bhatt, Ishaque Hameed, Stefan D. Anker, ALICE Y.Y. CHENG, Adrian F. Hernandez, W. Schuyler Jones, Muhammad Shahzeb Khan, Mark Colquhoun Petrie, Jacob Allen Udell et al. · 2024 · The Lancet Diabetes & Endocrinology
  49. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation
    Tuttle, Katherine R., Brosius, Frank C., Cavender, Matthew A., Fioretto, Paola, Fowler, Kevin J., Heerspink, Hiddo J.L., Manley, Tom, McGuire, Darren K., Molitch, Mark E., Mottl, Amy K. et al. · 2021 · Diabetes
  50. Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
    Christoffer Clemmensen, Brian Finan, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp, Susanna M. Hofmann · 2018 · Nature Reviews Endocrinology
  51. Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats
    H Oshima, Takayuki Miki, Atsushi Kuno, Masashi Mizuno, Tatsuya Sato, Masaya Tanno, Toshiyuki Yano, Kei Nakata, Yukishige Kimura, Koki Abe et al. · 2018 · Journal of Pharmacology and Experimental Therapeutics
  52. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
    Sin‐Hee Park, Muhammad A. Farooq, Sébastien Gaertner, C Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stéphan, Patrick Ohlmann et al. · 2020 · Cardiovascular Diabetology
  53. Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
    Ameya S Kulkarni, Sandra Aleksić, David M. Berger, Felipe Sierra, George A. Kuchel, Nir Barzilai · 2022 · Aging Cell
  54. Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus
    Ibrahim, Mahmoud, Davies, Melanie J, Ahmad, Ehtasham, Annabi, Firas A, Eckel, Robert H, Ba-Essa, Ebtesam M, El Sayed, Nuha Ali, Hess Fischl, Amy, Houeiss, Pamela, Iraqi, Hinde et al. · 2020 · BMJ Open Diabetes Research & Care
  55. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT Trial
    Scholtes, Rosalie A., Muskiet, Marcel H.A., van Baar, Michiel J.B., Hesp, Anne C., Greasley, Peter J., Karlsson, Cecilia, Hammarstedt, Ann, Arya, Niki, van Raalte, Daniël H., Heerspink, Hiddo J.L. · 2021 · Diabetes Care
  56. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
    Sarita Bajaj · 2018 · International Journal of Diabetes in Developing Countries
  57. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
    Agnes Bosch, Christian Ott, Susanne Jung, Kristina Striepe, Marina V. Karg, Dennis Kannenkeril, Thomas Dienemann, Roland Erich Schmieder · 2019 · Cardiovascular Diabetology
  58. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure
    Hidekazu Tanaka, Fumitaka Soga, Kazuhiro Tatsumi, Yasuhide Mochizuki, Hiroyuki Sano, Hiromi Toki, Kensuke Matsumoto, Junya Shite, Hideyuki Takaoka, Tomofumi Doi et al. · 2020 · Cardiovascular Diabetology
  59. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
    Li Shen, Søren Lund Kristensen, Olof Bengtsson, Michael Böhm, Rudolf A. de Boer, Kieran F. Docherty, Silvio E. Inzucchi, Tzvetana Katova, Lars Køber, Mikhail Kosiborod et al. · 2021 · JACC Heart Failure
  60. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
    Lorenzo Nesti, Domenico Tricò, Alessandro Mengozzi, Andrea Natali · 2021 · Cardiovascular Diabetology
  61. SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
    Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Tobias Sossalla · 2021 · Current Heart Failure Reports
  62. Non‐alcoholic fatty liver disease and type 2 diabetes: An update
    Chi‐Ho Lee, David Tak Wai Lui, Karen SL Lam · 2022 · Journal of Diabetes Investigation
  63. The benefits of GLP1 receptors in cardiovascular diseases
    Ferhatbegović, Lamija, Mršić, Denis, Macić-Džanković, Amra · 2023 · Frontiers in Clinical Diabetes and Healthcare
  64. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and <scp>SGLT</scp> 2s
    Thomas, Catherine E., Mauer, Elizabeth A., Shukla, Alpana P., Rathi, Samrat, Aronne, Louis J. · 2016 · Obesity
  65. Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity
    Gary D. Miller · 2017 · American Journal of Lifestyle Medicine
  66. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
    Subodh Verma, C. David Mazer, DAVID H. FITCHETT, Silvio E. Inzucchi, Egon Pfarr, Jyothis Thomas George, Bernard Zinman · 2018 · Diabetologia
  67. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
    Brian N. Finck · 2018 · Diabetes
  68. Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease
    Marc Yves Donath, Daniel T. Meier, Marianne Böni‐Schnetzler · 2019 · Endocrine Reviews
  69. Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021
    Fabiana G. Marcondes‐Braga, Lídia Zytynski Moura, Victor Sarli Issa, Jefferson Luís Vieira, Luís Eduardo Paim Rohde, Marcus Vinı́cius Simões, Miguel Morita Fernandes-Silva, Salvador Rassi, Sílvia Marinho Martins, Denílson Campos de Albuquerque et al. · 2021 · Arquivos Brasileiros de Cardiologia
  70. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
    Taylor, Simeon I, Blau, Jenny E, Rother, Kristina I, Beitelshees, Amber L · 2019 · The Lancet Diabetes &amp; Endocrinology
  71. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade
    Michael A. Weber, Traci A. Mansfield, Federica Alessi, Nayyar Iqbal, Shamik J. Parikh, Agata Ptaszynska · 2015 · Blood Pressure
  72. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
    Muthiah Vaduganathan, Vasanth Sathiyakumar, Avinainder Singh, Cian P. McCarthy, Arman Qamar, James L. Januzzi, Benjamin M. Scirica, Javed Butler, Christopher Paul Cannon, Deepak L. Bhatt · 2018 · Journal of the American College of Cardiology
  73. SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
    Yasuhiro Maejima · 2020 · Frontiers in Cardiovascular Medicine
  74. Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations
    Nadine E. Palermo, Archana Sadhu, Marie Elizabeth McDonnell · 2020 · The Journal of Clinical Endocrinology & Metabolism
  75. 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim et al. · 2023 · Diabetes & Metabolism Journal
  76. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
    Scheen, André J. · 2019 · Current Cardiology Reports
  77. Nephron Protection in Diabetic Kidney Disease
    Hans‐Joachim Anders, John M. Davis, Klaus Thurau · 2016 · New England Journal of Medicine
  78. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
    O’Meara, Eileen, McDonald, Michael, Chan, Michael, Ducharme, Anique, Ezekowitz, Justin A., Giannetti, Nadia, Grzeslo, Adam, Heckman, George A., Howlett, Jonathan G., Koshman, Sheri L. et al. · 2020 · Canadian Journal of Cardiology
  79. Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
    Rafael García Maset, Jordi Bover, J. Segura, Marian Goicoechea Diezhandino, Jesús Cebollada del Hoyo, Javier Escalada San Martín, Lorenzo Fácila, Javier Gamarra, José Antonio García‐Donaire, Lisardo García Matarin et al. · 2021 · Nefrología
  80. Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
    McCoy, Rozalina G., Dykhoff, Hayley J., Sangaralingham, Lindsey, Ross, Joseph S., Karaca-Mandic, Pinar, Montori, Victor M., Shah, Nilay D. · 2019 · Diabetes Technology &amp; Therapeutics
  81. Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
    Tatsuya Fukuda, Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara, Masahiro Asakawa, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama et al. · 2017 · Diabetes Therapy
  82. Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
    Mary E. Herman, James Henry O’Keefe, David S.H. Bell, Stanley S. Schwartz · 2017 · Progress in Cardiovascular Diseases
  83. Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
    Radica Z. Alicic, Joshua J. Neumiller, Emily J. Johnson, Brad P. Dieter, Katherine R. Tuttle · 2019 · Diabetes
  84. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
    Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii et al. · 2020 · Cardiovascular Diabetology
  85. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
    Byambasuren Ganbaatar, Daiju Fukuda, Masakazu Shinohara, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Ken‐ichi Hirata, Masataka Sata · 2020 · European Journal of Pharmacology
  86. Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
    Elisabetta Patorno, Ajinkya Pawar, Lily Gui Bessette, Dae Hyun Kim, Chintan V. Dave, Robert J. Glynn, Medha N. Munshi, Sebastian Schneeweiß, Deborah J. Wexler, Seoyoung C. Kim · 2021 · Diabetes Care
  87. Therapeutic Advances in Diabetic Nephropathy
    Hanny Sawaf, George Thomas, Jonathan J. Taliercio, Georges Nakhoul, Tushar J. Vachharajani, Ali Mehdi · 2022 · Journal of Clinical Medicine
  88. Diabetic cardiomyopathy
    Matthew M.Y. Lee, John J.V. McMurray, Ana Lorenzo-Almorós, Søren Lund Kristensen, Naveed A. Sattar, Pardeep S. Jhund, Mark Colquhoun Petrie · 2018 · Heart
  89. Personalized type 2 diabetes management: an update on recent advances and recommendations
    Williams, David M, Jones, Hannah, Stephens, Jeffrey W · 2022 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
  90. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study
    Javed, Zeeshan, Papageorgiou, Maria, Deshmukh, Harshal, Rigby, Alan S., Qamar, Unaiza, Abbas, Jehangir, Khan, Amer Y., Kilpatrick, Eric S., Atkin, Stephen L., Sathyapalan, Thozhukat · 2019 · Clinical Endocrinology
  91. Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction
    Kim Alexander Connelly, Yanling Zhang, Aylin Visram, Andrew Advani, Sri Nagarjun Batchu, Jean‐François Desjardins, Kerri Thai, Richard E. Gilbert · 2019 · JACC Basic to Translational Science
  92. Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway
    Xiangyang Liu, Chaofei Xu, Linxin Xu, Xiaoyu Li, Hongxi Sun, Mei Xue, Ting Li, Xiaochen Yu, Bei Sun, Liming Chen · 2020 · Metabolism
  93. Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review
    Michał Konwerski, Aleksandra Gąsecka, Grzegorz Opolski, Marcin Grabowski, Tomasz Mazurek · 2022 · Biology
  94. Do sulphonylureas still have a place in clinical practice?
    Khunti, Kamlesh, Chatterjee, Sudesna, Gerstein, Hertzel C, Zoungas, Sophia, Davies, Melanie J · 2018 · The Lancet Diabetes &amp; Endocrinology
  95. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial
    Bethel, M. Angelyn, Mentz, Robert J., Merrill, Peter, Buse, John B., Chan, Juliana C., Goodman, Shaun G., Iqbal, Nayyar, Jakuboniene, Neli, Katona, Brian, Lokhnygina, Yuliya et al. · 2020 · Diabetes Care
  96. Clinical management of the uraemic syndrome in chronic kidney disease
    Raymond Vanholder, Denis P. Fouque, Griet Glorieux, Gunnar Henrik Heine, Mehmet Kanbay, Francesca Mallamaci, Ziad A. Massy, Alberto Ortíz, Patrick Rossignol, Andrzej Więcek et al. · 2016 · The Lancet Diabetes & Endocrinology
  97. Type 2 Diabetes and Heart Failure: Challenges and Solutions
    Merlin C. Thomas · 2016 · Current Cardiology Reviews
  98. Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse
    Hotimah Masdan Salim, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro, Masataka Sata · 2016 · Frontiers in Cardiovascular Medicine
  99. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
    Gian Paolo Fadini, Benedetta Maria Bonora, Giancarlo Zatti, Nicola Vitturi, Elisabetta Iori, Maria Cristina Marescotti, Mattia Albiero, Angelo Avogaro · 2017 · Cardiovascular Diabetology
  100. Treatment with Insulin is Associated with Worse Outcome in Patients with Chronic Heart Failure and Diabetes
    Franco Cosmi, Li Shen, Michela Magnoli, William T. Abraham, Inder S. Anand, John G.F. Cleland, Jay N. Cohn, Deborah Cosmi, Giorgia De Berardis, Kenneth Dickstein et al. · 2018 · European Journal of Heart Failure